Humana is selling its minority stake in Gentiva, a leading end-of-life care provider, for $900 million. This divestiture is part of Humana's ongoing strategy to shed non-core assets and refocus on its CenterWell healthcare services business. The proceeds from the sale will be used for general corporate purposes, and the deal is anticipated to conclude in the third quarter, pending regulatory approval. AI
RANK_REASON A large divestiture by a major healthcare provider, indicating a strategic shift. [lever_c_demoted from significant: ic=1 ai=0.0]
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
